CoChat
Sign Up
Cited by 20

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery

Liu, Yilin, Zhang, Xiao, Chen, Xiaoyuan, Zhang, Fuwu·2026·Biomaterials
DOI 10.1016/j.biomaterials.2025.123621PMC PMC13281278
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biomaterials.2025.123621

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 8 references

Research works printed but not linked: 176

  1. Bekes, 2022, PROTAC targeted protein degraders: the past is prologue, Nat. Rev. Drug Discov., 21, 181, 10.1038/s41573-021-00371-6 · DOI · Paper page
  2. Wang, 2020, Degradation of proteins by PROTACs and other strategies, Acta Pharm. Sin. B, 10, 207, 10.1016/j.apsb.2019.08.001 · DOI · Paper page
  3. Zhao, 2022, Targeted protein degradation: mechanisms, strategies and application, Signal Transduct. Target. Ther., 7, 1413
  4. Li, 2022, Proteolysis-Targeting Chimeras (PROTACs) in cancer therapy: present and future, Molecules, 27, 8828, 10.3390/molecules27248828 · DOI
  5. Cai, 2024, Research progress of PROTACs for neurodegenerative diseases therapy, Bioorg. Chem., 147, 10.1016/j.bioorg.2024.107386 · DOI
  6. Zhao, 2023, Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics, Cell Host Microbe, 31, 1154, 10.1016/j.chom.2023.05.030 · DOI
  7. Gao, 2023, Stimuli-activatable PROTACs for precise protein degradation and cancer therapy, Sci. Bull., 68, 1069, 10.1016/j.scib.2023.04.028 · DOI
  8. Li, 2020, Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy, J. Hematol. Oncol., 13, 1, 10.1186/s13045-020-00885-3 · DOI
  9. Liu, 2022, An overview of PROTACs: a promising drug discovery paradigm, Mol. Biomed., 3, 46, 10.1186/s43556-022-00112-0 · DOI
  10. Wang, 2022, The state of the art of PROTAC technologies for drug discovery, European Eur. J. Med. Chem., 235
  11. Diehl, 2022, Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders, Chem. Soc. Rev., 51, 8216, 10.1039/D2CS00387B · DOI
  12. Chen, 2022, Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation, Chem. Soc. Rev., 51, 5330, 10.1039/D1CS00762A · DOI
  13. Zhu, 2023, Novel strategies and promising opportunities for targeted protein degradation: an innovative therapeutic approach to overcome cancer resistance, Pharmacol. Ther., 244, 10.1016/j.pharmthera.2023.108371 · DOI
  14. Schroder, 2024, DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance, Nat. Commun., 15, 275, 10.1038/s41467-023-44237-4 · DOI
  15. Zhang, 2023, Nano Proteolysis targeting chimeras (PROTACs) with anti-hook effect for tumor therapy, Angew. Chem. Int. Ed. Engl., 62, 10.1002/anie.202308049 · DOI
  16. Zeng, 2021, Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges, Eur. J. Med. Chem., 210, 10.1016/j.ejmech.2020.112981 · DOI
  17. Wang, 2024, PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: a review, Int. J. Biol. Macromol., 261, 10.1016/j.ijbiomac.2024.129864 · DOI
  18. Fan, 2024, Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment, Int. J. Biol. Macromol., 275, 10.1016/j.ijbiomac.2024.133680 · DOI
  19. Zhong, 2024, Nano-PROTACs: state of the art and perspectives, Nanoscale, 16, 4378, 10.1039/D3NR06059D · DOI
  20. Li, 2023, Targeted protein degradation in cancers: orthodox PROTACs and beyond, Innovation, 4
  21. Zhang, 2023, PROTAC nanoplatform with targeted degradation of NAD(P)H:Quinone oxidoreductase 1 to enhance reactive oxygen species-mediated apoptosis, ACS Appl. Mater. Interfaces, 15, 8946, 10.1021/acsami.2c20312 · DOI
  22. Kou, 2023, Development of liposome systems for enhancing the PK properties of bivalent PROTACs, Pharmaceutics, 15, 2098, 10.3390/pharmaceutics15082098 · DOI
  23. Naro, 2020, Optical control of small molecule-induced protein degradation, J. Am. Chem. Soc., 142, 2193, 10.1021/jacs.9b12718 · DOI
  24. Li, 2022, Proteolysis-targeting chimeras (PROTACs) in cancer therapy, Mol. Cancer, 21, 99, 10.1186/s12943-021-01434-3 · DOI
  25. Burslem, 2020, Proteolysis-targeting Chimeras as therapeutics and tools for biological discovery, Cell, 181, 102, 10.1016/j.cell.2019.11.031 · DOI · Paper page
  26. Nguyen, 2023, Proteolysis-targeting chimeras with reduced off-targets, Nat. Chem., 16, 218, 10.1038/s41557-023-01379-8 · DOI
  27. He, 2022, Strategies for designing proteolysis targeting chimaeras (PROTACs), Med. Res. Rev., 42, 1280, 10.1002/med.21877 · DOI
  28. Yao, 2022, Recent advances in PROTACs for drug targeted protein research, International Int. J. Mol. Sci., 23
  29. Loren, 2022, Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen, Eur. J. Med. Chem., 243, 10.1016/j.ejmech.2022.114770 · DOI
  30. Pu, 2023, Development of PROTAC degrader probe of CDK4/6 based on DCAF16, Bioorg. Chem., 138, 10.1016/j.bioorg.2023.106637 · DOI
  31. Zheng, 2021, Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP, J. Med. Chem., 64, 7839, 10.1021/acs.jmedchem.1c00649 · DOI
  32. Spradlin, 2019, Harnessing the anti-cancer natural product nimbolide for targeted protein degradation, Nat. Chem. Biol., 15, 747, 10.1038/s41589-019-0304-8 · DOI · Paper page
  33. Okuhira, 2013, Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells, Cancer Sci., 104, 1492, 10.1111/cas.12272 · DOI
  34. Brand, 2019, Homolog-selective degradation as a strategy to probe the function of CDK6 in AML, Cell Chem. Biol., 26, 300, 10.1016/j.chembiol.2018.11.006 · DOI · Paper page
  35. Sosic, 2022, E3 ligase ligand chemistries: from building blocks to protein degraders, Chem. Soc. Rev., 51, 3487, 10.1039/D2CS00148A · DOI
  36. Du, 2019, Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a sulfonamide molecular glue E7820, Structure, 27, 1625, 10.1016/j.str.2019.10.005 · DOI · Paper page
  37. Vu, 2013, Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development, ACS Med. Chem. Lett., 4, 466, 10.1021/ml4000657 · DOI · Paper page
  38. Fischer, 2014, Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide, Nature, 512, 49, 10.1038/nature13527 · DOI · Paper page
  39. Galdeano, 2014, Structure-guided design and optimization of small molecules targeting the protein protein interaction between the von Hippel- Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities, J. Med. Chem., 57, 8657, 10.1021/jm5011258 · DOI
  40. Lee, 2022, Discovery of E3 ligase ligands for target protein degradation, Molecules, 27, 6515, 10.3390/molecules27196515 · DOI
  41. Troup, 2020, Current strategies for the design of PROTAC linkers: a critical review, explor. Target, Antitumor Ther., 1, 273
  42. Wu, 2024, Potency-enhanced peptidomimetic VHL ligands with improved oral bioavailability, J. Med. Chem., 67, 8585, 10.1021/acs.jmedchem.3c02203 · DOI
  43. Si, 2023, Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction, Eur. J. Med. Chem., 257, 10.1016/j.ejmech.2023.115497 · DOI
  44. Grifagni, 2024, Development of a GC-376 based peptidomimetic PROTAC as a degrader of 3-chymotrypsin-like protease of SARS-CoV-2, ACS Med. Chem. Lett., 15, 250, 10.1021/acsmedchemlett.3c00498 · DOI
  45. Li, 2023, 3D based generative PROTAC linker design with reinforcement learning, Brief. Bioinform., 24, bbad323, 10.1093/bib/bbad323 · DOI
  46. Li, 2024, Application and challenges of nitrogen heterocycles in PROTAC linker, Eur. J. Med. Chem., 273, 10.1016/j.ejmech.2024.116520 · DOI
  47. Vartak, 2023, Cetuximab-based Proteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations, Int. J. Biol. Macromol., 252, 10.1016/j.ijbiomac.2023.126413 · DOI
  48. Zou, 2024, Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy, Acta Pharmacol. Sin., 45, 1740, 10.1038/s41401-024-01266-z · DOI
  49. Si, 2023, Design, synthesis and bioactivity evaluation of self-assembled PROTACs based on multi-target kinase inhibitors, Bioorg. Chem., 134, 10.1016/j.bioorg.2023.106439 · DOI
  50. Liu, 2023, Aptamer-based targeted protein degradation, ACS Nano, 17, 6150, 10.1021/acsnano.2c10379 · DOI
  51. Zhu, 2023, Recent advance in tailoring the structure and functions of self-assembled peptide nanomaterials for biomedical applications, Coord. Chem. Rev., 494, 10.1016/j.ccr.2023.215374 · DOI
  52. Chang, 2023, Functional chromopeptide nanoarchitectonics: molecular design, self-assembly and biological applications, Chem. Soc. Rev., 52, 2688, 10.1039/D2CS00675H · DOI
  53. Lin, 2024, Bifunctional peptide nanofibrils for targeted protein degradation, Angew. Chem. Int. Ed. Engl., 63, 10.1002/anie.202316581 · DOI
  54. Si, 2023, Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy, Bioorg. Chem., 135, 10.1016/j.bioorg.2023.106497 · DOI
  55. Wang, 2023, CDK4/6 nano-PROTAC enhances mitochondria-dependent photodynamic therapy and anti-tumor immunity, Nano Today, 50, 10.1016/j.nantod.2023.101890 · DOI
  56. Zhao, 2024, Chemotherapy-enabled colorectal cancer immunotherapy of self-delivery nano-PROTACs by inhibiting tumor glycolysis and avoiding adaptive immune resistance, Adv. Sci., 11, 10.1002/advs.202309204 · DOI
  57. Yang, 2023, Targeted biomolecule regulation platform: a split-and-mix PROTAC approach, J. Am. Chem. Soc., 145, 7879, 10.1021/jacs.2c12824 · DOI
  58. Baietti, 2023, Novel therapeutic approaches targeting post-translational modifications in lung cancer, Pharmaceutics, 15, 206, 10.3390/pharmaceutics15010206 · DOI
  59. Grimaldi, 2016, Lipid-based nanovesicles for nanomedicine, Chem. Soc. Rev., 45, 6520, 10.1039/C6CS00409A · DOI
  60. Luo, 2022, Intracellular delivery of glutathione peroxidase degrader induces ferroptosis in vivo, Angew. Chem. Int. Ed. Engl., 61, 10.1002/anie.202206277 · DOI
  61. Chen, 2021, Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles, J. Contr. Release, 330, 1244, 10.1016/j.jconrel.2020.11.032 · DOI
  62. Yao, 2023, Exploiting cancer vulnerabilities by blocking of the DHODH and GPX4 pathways: a multifunctional bodipy/PROTAC nanoplatform for the efficient synergistic ferroptosis therapy, Adv. Healthc. Mater., 12, 10.1002/adhm.202300871 · DOI
  63. Song, 2023, Selective protein of interest degradation through the split-and-mix liposome proteolysis targeting chimera approach, J. Am. Chem. Soc., 145, 21860, 10.1021/jacs.3c05948 · DOI
  64. Nguyen, 2023, Advances in drug delivery systems based on red blood cells and their membrane-derived nanoparticles, ACS Nano, 17, 5187, 10.1021/acsnano.2c11965 · DOI
  65. Zhang, 2022, Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy, Adv. Sci., 9, 10.1002/advs.202202039 · DOI
  66. Dilliard, 2023, Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs, Nat. Rev. Mater., 8, 282, 10.1038/s41578-022-00529-7 · DOI
  67. Zhang, 2023, Functionalization of polymers for intracellular protein delivery, Prog. Polym. Sci., 146, 10.1016/j.progpolymsci.2023.101751 · DOI
  68. Cimas, 2020, Controlled delivery of BET-PROTACs: in vitro evaluation of MZ1-loaded polymeric antibody conjugated nanoparticles in breast cancer, Pharmaceutics, 12, 986, 10.3390/pharmaceutics12100986 · DOI
  69. Ma, 2024, Folate-PEG-PROTAC micelles for enhancing tumor-specific targeting proteolysis in vivo, Adv. Healthc. Mater., 13, 10.1002/adhm.202400109 · DOI
  70. Liu, 2023, Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects, Adv. Sci., 10, 10.1002/advs.202207439 · DOI
  71. Sun, 2023, Conjugated polyelectrolyte/single strand DNA hybrid polyplexes for efficient nucleic acid delivery and targeted protein degradation, ACS Appl. Mater. Interfaces, 16, 19987
  72. Gao, 2022, Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy, Nat. Commun., 13, 4318, 10.1038/s41467-022-32050-4 · DOI
  73. Tao, 2024, Aromatic short peptide architectonics: assembly and engineering, Prog. Mater. Sci., 142, 10.1016/j.pmatsci.2024.101240 · DOI
  74. Zhang, 2022, Microfabrication of peptide self-assemblies: inspired by nature towards applications, Chem. Soc. Rev., 51, 6936, 10.1039/D2CS00122E · DOI
  75. Shi, 2023, Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells, Front. Immunol., 14, 10.3389/fimmu.2023.1193222 · DOI
  76. Ma, 2020, A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer, Theranostics, 10, 3708, 10.7150/thno.41677 · DOI
  77. Jin, 2020, The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination, Theranostics, 10, 10141, 10.7150/thno.46985 · DOI
  78. Sun, 2020, Acid-activatable transmorphic peptide-based nanomaterials for photodynamic therapy, Angew. Chem. Int. Ed. Engl., 59, 20582, 10.1002/anie.202008708 · DOI
  79. Liu, 2025, Transformable peptide blocks NF-xB/IxBα pathway through targeted coating IxBα against rheumatoid arthritis, Biomaterials, 314, 10.1016/j.biomaterials.2024.122839 · DOI
  80. Chen, 2024, Sulfatase-induced in situ formulation of antineoplastic supra-PROTACs, J. Am. Chem. Soc., 146, 10753, 10.1021/jacs.4c00826 · DOI
  81. Liu, 2023, Emodin-based nanoarchitectonics with giant two-photon absorption for enhanced photodynamic therapy, Angew. Chem. Int. Ed. Engl., 62, 10.1002/anie.202308019 · DOI
  82. Dragovich, 2020, Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα), Bioorg. Med. Chem. Lett., 30, 10.1016/j.bmcl.2019.126907 · DOI · Paper page
  83. Solomonov, 2024, Designing multifunctional biomaterials via protein self-assembly, Angew. Chem. Int. Ed. Engl., 63, 10.1002/anie.202318365 · DOI
  84. Fu, 2024, Protein-based bioactive coatings: from nanoarchitectonics to applications, Chem. Soc. Rev., 53, 1514, 10.1039/D3CS00786C · DOI
  85. Cho, 2023, In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy, Biomaterials, 295, 10.1016/j.biomaterials.2023.122038 · DOI
  86. Chen, 2023, Small-molecule ferritin degrader as a pyroptosis inducer, J. Am. Chem. Soc., 145, 9815, 10.1021/jacs.3c01852 · DOI
  87. Chan, 2023, Antibody-proteolysis targeting chimera conjugate enables selective degradation of receptor-interacting serine/threonine-protein kinase 2 in HER2+ cell lines, Bioconjug. Chem., 34, 2049, 10.1021/acs.bioconjchem.3c00366 · DOI
  88. Ji, 2023, Application of intelligent responsive DNA self-assembling nanomaterials in drug delivery, J. Contr. Release, 361, 803, 10.1016/j.jconrel.2023.08.036 · DOI
  89. Xie, 2023, Aptamer-based targeted delivery of functional nucleic acids, J. Am. Chem. Soc., 145, 7677, 10.1021/jacs.3c00841 · DOI
  90. Zhou, 2023, DNA framework-engineered chimeras platform enables selectively targeted protein degradation, Nat. Commun., 14, 4510, 10.1038/s41467-023-40244-7 · DOI
  91. Shao, 2021, Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O'PROTAC): effective targeting of LEF1 and ERG, Adv. Sci., 8
  92. Hall, 2024, Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3, Mol. Ther. Nucleic Acids, 35, 10.1016/j.omtn.2024.102137 · DOI
  93. He, 2021, Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer, Angew. Chem. Int. Ed. Engl., 60, 23299, 10.1002/anie.202107347 · DOI
  94. He, 2024, Drugtamer-PROTAC conjugation strategy for targeted PROTAC delivery and synergistic antitumor therapy, Adv. Sci., 11, 10.1002/advs.202401623 · DOI
  95. Zhang, 2022, Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin, Mol. Ther. Nucleic Acids, 30, 66, 10.1016/j.omtn.2022.09.008 · DOI
  96. Yang, 2022, Red-light-triggered self-destructive mesoporous silica nanoparticles for cascade-amplifying chemo-photodynamic therapy favoring antitumor immune responses, Biomaterials, 281, 10.1016/j.biomaterials.2022.121368 · DOI
  97. Moreno-Alcantar, 2023, Gold complexes in anticancer therapy: from new design principles to particle-based delivery systems, Angew. Chem. Int. Ed. Engl., 62, 10.1002/anie.202218000 · DOI
  98. Huang, 2023, Silver doped-silica nanoparticles reinforced poly (ethylene glycol) diacrylate/hyaluronic acid hydrogel dressings for synergistically accelerating bacterial-infected wound healing, Carbohydr. Polym., 304, 10.1016/j.carbpol.2022.120450 · DOI
  99. He, 2023, Near-infrared-activatable PROTAC nanocages for controllable target protein degradation and on-demand antitumor therapy, J. Med. Chem., 66, 10458, 10.1021/acs.jmedchem.3c00587 · DOI
  100. Wu, 2023, A physiologically responsive nanocomposite hydrogel for treatment of head and neck squamous cell carcinoma via proteolysis-targeting chimeras enhanced immunotherapy, Adv. Mater., 35, 10.1002/adma.202210787 · DOI
  101. Wang, 2023, Persistent degradation of HER2 protein by hybrid nanoPROTAC for programmed cell death, J. Med. Chem., 66, 6263, 10.1021/acs.jmedchem.3c00013 · DOI
  102. Yang, 2023, Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2, J. Adv. Res., 45, 59, 10.1016/j.jare.2022.05.009 · DOI
  103. Ma, 2022, De novo design of an androgen receptor DNA binding domain-targeted peptide PROTAC for prostate cancer therapy, Adv. Sci., 9, 10.1002/advs.202201859 · DOI
  104. Jung, 2022, Self-deliverable and self-immolative prodrug nanoassemblies as tumor targeted nanomedicine with triple cooperative anticancer actions, Biomaterials, 287, 10.1016/j.biomaterials.2022.121681 · DOI
  105. Wen, 2023, Controlled sequential in situ self-assembly and disassembly of a fluorogenic cisplatin prodrug for cancer theranostics, Nat. Commun., 14, 800, 10.1038/s41467-023-36469-1 · DOI
  106. Li, 2024, Pillararene-based stimuli-responsive supramolecular delivery systems for cancer therapy, Adv. Mater., 36
  107. Choi, 2024, Light-triggered PROTAC nanoassemblies for photodynamic IDO proteolysis in cancer immunotherapy, Adv. Mater., 36
  108. Bi, 2023, Rational design of bioorthogonally activatable PROTAC for tumor-targeted protein degradation, J. Med. Chem., 66, 14843, 10.1021/acs.jmedchem.3c01423 · DOI
  109. 2023, Assembled photosensitizers applied for enhanced photodynamic therapy, CCS Chem., 5, 1043, 10.31635/ccschem.023.202302711 · DOI
  110. Zhou, 2023, In vivo metallophilic self-assembly of a light-activated anticancer drug, Nat. Chem., 15, 980, 10.1038/s41557-023-01199-w · DOI
  111. Han, 2023, The design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy, Chem. Soc. Rev., 52, 879, 10.1039/D2CS00673A · DOI
  112. Wang, 2020, PhotoPROTACs: a novel biotechnology for cancer treatment, Trends Cell Biol., 30, 749, 10.1016/j.tcb.2020.08.003 · DOI
  113. Reynders, 2020, PHOTACs enable optical control of protein degradation, Sci. Adv., 6, 10.1126/sciadv.aay5064 · DOI
  114. Liu, 2020, Light-induced control of protein destruction by opto-PROTAC, Sci. Adv., 6, 10.1126/sciadv.aay5154 · DOI
  115. Wang, 2023, A metal-phenolic nanocoordinator launches radiotherapeutic cancer pyroptosis through an epigenetic mechanism, Adv. Funct. Mater., 33, 10.1002/adfm.202213425 · DOI
  116. Zhang, 2023, STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma, Nat. Commun., 14, 1610, 10.1038/s41467-023-37328-9 · DOI
  117. Zhang, 2022, Radiotherapy combined with immunotherapy: the dawn of cancer treatment, Signal Transduct. Target. Ther., 7, 258, 10.1038/s41392-022-01102-y · DOI
  118. Zhang, 2024, PROTAC prodrug-integrated nanosensitizer for potentiating radiation therapy of cancer, Adv. Mater., 36, 10.1002/adma.202314132 · DOI
  119. Yang, 2022, Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors, J. Am. Chem. Soc., 145, 385, 10.1021/jacs.2c10177 · DOI
  120. Xu, 2024, Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy, J. Mater. Chem. B, 12, 3240, 10.1039/D3TB03046F · DOI
  121. Zhao, 2024, Glutathione-triggered prodrugs: design strategies, potential applications, and perspectives, Med. Res. Rev., 44, 1013, 10.1002/med.22007 · DOI
  122. Kondengadan, 2024, Quantitative factors introduced in the feasibility analysis of reactive oxygen species (ROS)-sensitive triggers, Angew. Chem. Int. Ed. Engl., 63, 10.1002/anie.202403880 · DOI
  123. Huang, 2023, Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy, J. Contr. Release, 361, 270, 10.1016/j.jconrel.2023.07.062 · DOI
  124. Wei, 2021, First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo, Eur. J. Med. Chem., 209, 10.1016/j.ejmech.2020.112903 · DOI
  125. Liu, 2022, Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation, Chem. Commun., 58, 10072, 10.1039/D2CC03367D · DOI
  126. Wang, 2024, Liposomal STAT3-degrading PROTAC prodrugs promote anti-hepatocellular carcinoma immunity via chemically reprogramming cancer stem cells, Nano Lett., 24, 4858
  127. He, 2023, Enhanced tumor targeting and penetration of proteolysis-targeting chimeras through iRGD peptide conjugation: a strategy for precise protein degradation in breast cancer, J. Med. Chem., 66, 16828, 10.1021/acs.jmedchem.3c01539 · DOI · Paper page
  128. Fan, 2023, Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors, Bioorg. Chem., 140, 10.1016/j.bioorg.2023.106793 · DOI
  129. Zhang, 2023, Hyaluronic acid-based prodrug nanomedicines for enhanced tumor targeting and therapy: a review, Int. J. Biol. Macromol., 249, 10.1016/j.ijbiomac.2023.125993 · DOI
  130. Martin, 2022, Glycosidase activated prodrugs for targeted cancer therapy, Chem. Soc. Rev., 51, 9694, 10.1039/D2CS00379A · DOI
  131. Thang Cong, 2022, Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras, Sci. Adv., 8
  132. 2022, Enzyme-catalyzed activation of pro-PROTAC for cell-selective protein degradation, CCS Chem., 4, 3809, 10.31635/ccschem.022.202101529 · DOI
  133. Liu, 2022, Small-molecule PROTACs for cancer immunotherapy, Molecules, 27, 5439, 10.3390/molecules27175439 · DOI
  134. Liang, 2024, Inherent tumor microenvironment-reversing hydrogels: potentiating molecular therapy efficacy against drug-resistant tumors, Adv. Funct. Mater., 34, 10.1002/adfm.202314772 · DOI
  135. Zhao, 2022, Super light-sensitive photosensitizer nanoparticles for improved photodynamic therapy against solid tumors, Angew. Chem. Int. Ed. Engl., 61, 10.1002/anie.202210920 · DOI
  136. Li, 2021, Metal-free nanoassemblies of water-soluble photosensitizer and adenosine triphosphate for efficient and precise photodynamic cancer therapy, ACS Nano, 15, 4979, 10.1021/acsnano.0c09913 · DOI
  137. Huang, 2024, A PROTAC augmenter for photo-driven pyroptosis in breast cancer, Adv. Mater., 36, 10.1002/adma.202313460 · DOI
  138. Wang, 2023, Self-assembled nano-PROTAC enables near-infrared photodynamic proteolysis for cancer therapy, J. Am. Chem. Soc., 145, 16642, 10.1021/jacs.3c04109 · DOI
  139. Zhang, 2023, Checkpoint nano-PROTACs for activatable cancer photo-immunotherapy, Adv. Mater., 35, 10.1002/adma.202208553 · DOI
  140. Liu, 2020, Two-dimensional nanomaterials for photothermal therapy, Angew. Chem. Int. Ed. Engl., 59, 5890, 10.1002/anie.201911477 · DOI
  141. Li, 2021, Near infrared photothermal conversion materials: mechanism, preparation, and photothermal cancer therapy applications, J. Mater. Chem. B, 9, 7909, 10.1039/D1TB01310F · DOI
  142. Li, 2025, Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy, Biomaterials, 322, 10.1016/j.biomaterials.2025.123387 · DOI
  143. Liu, 2022, 2D-PROTACs with augmented protein degradation for super-resolution photothermal optical coherence tomography guided momentary multimodal therapy, Chem. Eng. J., 446, 10.1016/j.cej.2022.137039 · DOI
  144. Hu, 2023, Tailoring albumin-based theranostic PROTACs nanoparticles for enhanced NIR-II bioimaging and synergistic cancer chemo-phototherapy, Chem. Eng. J., 469, 10.1016/j.cej.2023.143883 · DOI
  145. Kong, 2024, An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer, Sci. Bull., 69, 2122, 10.1016/j.scib.2024.05.017 · DOI
  146. Hashemi, 2023, Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies, Biomed. Pharmacother., 160, 10.1016/j.biopha.2023.114392 · DOI · Paper page
  147. Wang, 2024, Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance, Drug Resist. Updat., 72, 10.1016/j.drup.2023.101018 · DOI
  148. He, 2023, Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy, J. Contr. Release, 354, 155, 10.1016/j.jconrel.2022.12.035 · DOI
  149. He, 2022, Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles, Mater. Today Bio, 16
  150. Sun, 2024, Reactive oxygen species responsive chitooligosaccharides based nanoplatform for sonodynamic therapy in mammary cancer, Carbohydr. Polym., 342, 10.1016/j.carbpol.2024.122403 · DOI
  151. Duan, 2023, Reticular chemistry-enabled sonodynamic activity of covalent organic frameworks for nanodynamic cancer therapy, Angew. Chem. Int. Ed. Engl., 62, 10.1002/anie.202302146 · DOI
  152. Liu, 2024, Ultrasound-activated PROTAC prodrugs overcome immunosuppression to actuate efficient deep-tissue sono-immunotherapy in orthotopic pancreatic tumor mouse models, Nano Lett., 24, 8741, 10.1021/acs.nanolett.4c02287 · DOI
  153. Wang, 2024, Dual-programmable semiconducting polymer nanoPROTACs for deep-tissue sonodynamic-ferroptosis activatable immunotherapy, Small, 20, 10.1002/smll.202306378 · DOI
  154. Wu, 2022, NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion, Acta Pharm. Sin. B, 12, 2859, 10.1016/j.apsb.2021.12.017 · DOI
  155. Zhu, 2023, Nanomaterials in tumor immunotherapy: new strategies and challenges, Mol. Cancer, 22, 94, 10.1186/s12943-023-01797-9 · DOI
  156. Murciano-Goroff, 2020, The future of cancer immunotherapy: microenvironment-targeting combinations, Cell Res., 30, 507, 10.1038/s41422-020-0337-2 · DOI
  157. Kolb, 2021, Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells, Nat. Commun., 12, 1281, 10.1038/s41467-021-21573-x · DOI
  158. Moon, 2023, Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy, Pharmaceutics, 15, 411, 10.3390/pharmaceutics15020411 · DOI
  159. Su, 2023, Targeted degradation of PD-L1 and activation of the STING pathway by carbon-dot-based PROTACs for cancer immunotherapy, Angew. Chem. Int. Ed. Engl., 62, 10.1002/anie.202218128 · DOI
  160. Chen, 2024, Synergizing CXCL9 with BRD4-PROTAC using nanochaperone boosts robust T cell-dependent antitumor immune responses for cancer immunotherapy, Adv. Funct. Mater., 34, 10.1002/adfm.202314203 · DOI
  161. Zhang, 2022, Smart nano-PROTACs reprogram tumor microenvironment for activatable photo-metabolic cancer immunotherapy, Angew. Chem. Int. Ed. Engl., 61, 10.1002/anie.202114957 · DOI
  162. Yang, 2023, Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy, J. Hematol. Oncol., 16, 59, 10.1186/s13045-023-01453-1 · DOI
  163. Zhang, 2021, Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy, Nat. Commun., 12, 2934, 10.1038/s41467-021-23194-w · DOI
  164. Wang, 2024, Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma, bioRxiv
  165. Huang, 2025, Targeted degradation of ZBP1 with covalent PROTACs for anti-inflammatory treatment of infections, Angew. Chem. Int. Ed. Engl.
  166. Dong, 2024, Heat shock protein 90 interactome-mediated proteolysis targeting chimera (HIM-PROTAC) degrading glutathione peroxidase 4 to trigger ferroptosis, J. Med. Chem., 67, 16712, 10.1021/acs.jmedchem.4c01518 · DOI
  167. Y. Chen, S. Pal, W. Li, F. Liu, S. Yuan, Q. Hu, Engineered platelets as targeted protein degraders and application to breast cancer models, Nat. Biotechnol. doi: 10.1038/s41587-024-02494-8. · DOI
  168. Moon, 2025, Dendritic cell maturation in cancer, Nat. Rev. Cancer, 25, 225, 10.1038/s41568-024-00787-3 · DOI
  169. Luri-Rey, 2025, Cross-priming in cancer immunology and immunotherapy, Nat. Rev. Cancer, 25, 249, 10.1038/s41568-024-00785-5 · DOI
  170. Zhao, 2025, Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates, Nat. Biomed. Eng., 9, 1
  171. Wilhelm, 2016, Analysis of nanoparticle delivery to tumours, Nat. Rev. Mater., 1, 1, 10.1038/natrevmats.2016.14 · DOI · Paper page
  172. Zhang, 2025, Unconventional PROTACs for targeted protein degradation in cancer therapy, Angew. Chem. Int. Ed. Engl.
  173. Fu, 2025, Smart polymer prodrugs via responsive prodrug-initiated ring-opening polymerization of lactide for improved drug delivery, Nanoscale, 17, 10595, 10.1039/D5NR00780A · DOI
  174. Fu, 2025, Redox-sensitive camptothecin prodrug: a promising drug delivery strategy with ultrahigh drug loading and tunable drug release, Nano TransMed, 4, 10.1016/j.ntm.2025.100088 · DOI
  175. Yao, 2025, An oral PROTAC targeting HPK1 degradation potentiates anti-solid tumor immunity, Adv. Mater., 37, 10.1002/adma.202411454 · DOI
  176. Rao, 2024, Designing nanotheranostics with machine learning, Nat. Nanotechnol., 19, 1769, 10.1038/s41565-024-01753-8 · DOI

Cited by

Sorted by citations

See all 20

Metadata

Authors
Liu, Y., Zhang, X., Chen, X., & Zhang, F.
Venue
Biomaterials
Publisher
Elsevier BV
Published
2026-02
Volume
325
Pages
123621
ISSN
0142-9612
DOI
10.1016/j.biomaterials.2025.123621
PMC
PMC13281278
Cited by
20
References
8
Language
en
Licence
Funders
  • National University of Singapore
  • National Institute of General Medical Sciences
  • National Institutes of Health (R35GM155068)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review